Edwards Lifesciences Corporation (EW): Price and Financial Metrics
Edwards Lifesciences Corporation (EW)
Today's Latest Price: $80.41 USD
Updated Oct 23 7:00pm
Add EW to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 142 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
EW Stock Summary
- EW has a higher market value than 96.11% of US stocks; more precisely, its current market capitalization is $51,983,729,977.
- With a one year PEG ratio of 4,940.78, Edwards Lifesciences Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 99.32% of US stocks.
- In terms of volatility of its share price, EW is more volatile than 92.38% of stocks we're observing.
- Stocks that are quantitatively similar to EW, based on their financial statements, market capitalization, and price volatility, are CSGP, ATVI, TEL, PHG, and BIIB.
- EW's SEC filings can be seen here. And to visit Edwards Lifesciences Corp's official web site, go to www.edwards.com.
EW Stock Price Chart Interactive Chart >
EW Price/Volume Stats
| Current price | $80.41 | 52-week high | $87.79 |
| Prev. close | $79.38 | 52-week low | $51.51 |
| Day low | $79.07 | Volume | 2,500,571 |
| Day high | $80.52 | Avg. volume | 3,657,628 |
| 50-day MA | $81.63 | Dividend yield | N/A |
| 200-day MA | $74.38 | Market Cap | 49.99B |
Edwards Lifesciences Corporation (EW) Company Bio
Edwards Lifesciences provides products and technologies to treat structural heart disease and critically ill patients worldwide. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The company was founded in 1999 and is based in Irvine, California.
EW Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $80.41 | $11.25 | -87% |
We started the process of determining a valid price forecast for Edwards Lifesciences Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Edwards Lifesciences Corp ranked in the 13th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Edwards Lifesciences Corp ended up being:
- The compound growth rate in the free cash flow of Edwards Lifesciences Corp over the past 5.44 years is 0%; that's better than only 19.21% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet suggests that 1% of the company's capital is sourced from debt; this is greater than merely 6.5% of the free cash flow producing stocks we're observing.
- EW's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 54.14% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -87% |
| 1% | -87% |
| 2% | -87% |
| 3% | -86% |
| 4% | -86% |
| 5% | -86% |
BSX, ELAN, TECH, BLFS, and LGND can be thought of as valuation peers to EW, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...